Analysis of 4-methylthioamphetamine in clinical specimens

Simon P Elliott

From the Regional Laboratory for Toxicology, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK

SUMMARY. There has been much publicity, particularly in Europe, regarding a new phenylethylamine-based compound called 4-methylthioamphetamine (4-MTA), also known as para-methylthioamphetamine (p-MTA). Chemically, 4-MTA is an amphetamine derivative and is a potent, non-neurotoxic serotonin-releasing agent and reversible inhibitor of rat monoamine oxidase-A. Its effects, therefore, appear different from those of amphetamine.

Analysis of various plasma and urine specimens in three clinical cases implicating ‘Ecstasy’ ingestion revealed the presence of 4-MTA. Presumed metabolites were also detected, with one compound identified as being 4-MTA sulfoxide. The concentrations of 4-MTA measured in the plasma ranged from 0.131 mg/L to 0.760 mg/L. In one patient the 4-MTA concentration was determined in a series of plasma samples and this allowed a presumptive half-life of approximately 7 h to be estimated. This paper describes the first reported data regarding possible pharmacokinetics of 4-MTA in humans and presents the first reported non-fatal instances of 4-MTA intoxication in the UK.

INTRODUCTION

4-methylthioamphetamine (4-MTA), also known as para-methylthioamphetamine (p-MTA) or MTA, was first synthesized in 1992 by Nichol et al. Chemically, 4-MTA is an amphetamine derivative (see Fig. 1) and potent psychoactive compound, but it exhibits different effects from those of amphetamine and LSD. Studies also indicated that 4-MTA is a potent, dose-dependent serotonin-releasing agent and reversible inhibitor of rat monoamine oxidase-A (MAO-A). At behaviourally relevant doses in rats it appeared to be non-neurotoxic, but at high doses serotonergic behaviour was observed. Additional animal studies suggested it also had a delayed reaction compared to the 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)–related compounds studied.

Tablets containing 4-MTA were first seized in Europe in 1997, with the street-name ‘Flatliner’ or ‘S5’; however, they are usually sold as Ecstasy. Nevertheless, 4-MTA-containing tablets comprise only a very small proportion of illicitly available Ecstasy tablets (King L, Groombridge C, personal communication, 1998, 1999). It is common for tablets (especially Flatliners) to contain only 4-MTA, but some S5 tablets have been found to contain caffeine as well. Since 1997, various numbers of tablets containing 4-MTA have been seized in sporadic batches across Europe and also in Australia, with most having been seized in the UK (King L, Groombridge C, personal communication, 1998, 1999).

Users have noted that 4-MTA produces a greater ‘high’ and has a delayed reaction compared to ‘normal’ Ecstasy, thereby supporting the animal data; the latter characteristic can therefore result in accidental overdose if the user takes additional tablets while waiting for an effect (Thomas, personal communication 1998, 1999). It is believed to have been implicated in seven deaths worldwide (five in the UK, one in the Netherlands and one in France) and at least 10 reported cases of non-fatal intoxication (four in the UK, five in Belgium and one in the Netherlands) since 1997 (European Monitoring Centre for Drugs and Drug Addiction, personal communication, 1999, 2000). 4-MTA alone has only been detected in one of the deaths reported, and both fatal and non-fatal intoxications invariably involve additional drugs.

Therefore, owing to the limited number of instances where 4-MTA has been encountered,
the exact mechanism of 4-MTA poisoning has yet to be ascertained. However, in most cases the patient/deceased experienced convulsions and respiratory depression.

This paper describes the detection and quantification of 4-MTA in human plasma by high-performance liquid chromatography with diode array UV detection (HPLC-DAD), in three clinical investigations involving intoxication with this drug, in which the patients survived. The presence of additional drugs and the plasma concentrations of other amphetamine derivatives (i.e. amphetamine and MDMA) detected during toxicological screening are also presented. Although these cases occurred 2 years ago there are still very few published data regarding non-fatal instances of 4-MTA intoxication and resultant plasma concentrations, in particular preliminary human pharmacokinetic data. Therefore, the author believes these to be the first reported data regarding the possible pharmacokinetics of 4-MTA in humans, and also to represent the first reported non-fatal instances of 4-MTA intoxication in the UK.

![Chemical structure of 4-methylthioamphetamine.](image1)

![UV spectra of (a) 3,4-methylenedioxymethamphetamine (MDMA), (b) amphetamine, (c) 4-methylthioamphetamine (4-MTA) and two associated compounds, (d) 4-MTA associated compound 1 and (e) 4-MTA sulphoxide.](image2)
Figure 2. continued.
**MATERIALS AND METHODS**

**Chromatographic equipment**

HPLC-DAD analysis was performed using a M480 high-precision pump, a column oven, a Gina 50 autosampler and a UVD340S diode array detector, all from Dionex UK (Macclesfield, Cheshire, UK), with an X-Act 4-channel degasser from Jour Research. A Waters Spherisorb S5OD/CN 4.6 mm × 150 mm cartridge column (Watford, UK), protected by a 4 mm × 10 mm guard column of Spherisorb S5ODS2, was used for the analysis. Data acquisition was handled by a Dionex Chromelcon software package running on an Elonex MMX Pentium PC (233 MHz, 128 Mb RAM), with the diode-

---

**FIGURE 3.** Chromatograms obtained from (a) case 1, (b) case 2 and (c) case 3 following qualitative high-performance liquid chromatography with diode array UV detection analysis of 0.5 mL of human urine at pH 10 after solvent extraction and acid back extraction. Injection volume was 30 µL. MTA = methylthioamphetamine; assoc = associated compound; MDMA = 3,4-methylenedioxyamphetamine.
array detector recording spectral data between 200 nm and 595 nm.

Materials
The 1.0 mol/L triethylammonium phosphate (TEAP) buffer (pH 3.0) was supplied by Fluka, Gillingham, Dorset, UK, and the HPLC-grade acetonitrile was supplied by Rathburn Chemicals Ltd, Walkerburn, Scotland. The HPLC-grade 1-chlorobutane was obtained from Fisher Scientific International, Loughborough, UK. MDMA, fenfluramine hydrochloride and amphetamine...
sulphate were supplied by Sigma-Aldrich, Poole, Dorset, UK. Pure 4-MTA hydrochloride was kindly supplied by Drs Huizer and Poortman (Forensic Science Laboratory, Rijswijk, The Netherlands) and was used to prepare reference and calibration standards for the formal identification and quantification of 4-MTA in the specimens analysed. Calibration standards with assigned values of 0.05, 1.25 and 5 mg/L 4-MTA were prepared in blank equine plasma. Two further standards with values of 0.05 mg/L and 0.02 mg/L were also produced to determine the limit of detection of the assay.

Extraction methods for biological specimens

**HPLC-DAD screening**

Five hundred microlitres of Na$_2$CO$_3$, 200 mmol/L pH 10, were added to 500 μL of blood/urine followed by 5 μL of 1-chlorobutane in a 12 mL polypropylene tube. After shaking for 3 min and following centrifugation at 4500 rpm for 3 min, the supernatant was transferred to a second tube. Drugs were extracted into 100 μL 50 mmol/L H$_2$SO$_4$, shaken for 3 min, centrifuged at 3500 rpm for 3 min, and then the supernatant was aspirated and the acid layer transferred into a vial for injection. The injection volume was 30 μL.

**HPLC-DAD quantification**

Five hundred microlitres of 10 mg/L fenfluramine internal standard (in 200 mmol/L Na$_2$CO$_3$ solution) was added to 500 μL of sample/standard, followed by extraction with 5 mL 1-chlorobutane and back extraction with 100 μL 50 mmol/L H$_2$SO$_4$, as for the screening procedure detailed above. The injection volume was 20 μL.

**Chromatography conditions**

For HPLC-DAD screening a single-step gradient elution was performed using a mixed mobile phase. Mobile phase A consisted of 700 mL 99.9% HPLC-grade acetonitrile together with 25 mL 1 mol/L TEAP buffer (pH 3.0) diluted with 275 mL HPLC-grade water to give a final concentration of 25 mmol/L buffer and 70% acetonitrile. Mobile phase B consisted of 25 mL 1 mmol/L TEAP buffer diluted with 975 mL HPLC-grade water to give a final concentration of 25 mmol/L buffer. The elution conditions for the gradient were achieved using a 2 mL/min flow rate of 0–70% acetonitrile for 15 min, and then holding at 70% acetonitrile for 3 min. The column temperature was maintained at 25°C. The 4-MTA quantification procedure was based on 20% acetonitrile (in 25 mmol/L TEAP

---

Figure 4. continued.
buffer) isocratic elution at a flow rate of 2 mL/min. For amphetamine and MDMA quantitative analysis, 10% acetonitrile isocratic conditions at a flow rate of 2 mL/min were used. The column temperature was maintained at 25°C.

RESULTS AND DISCUSSION

Qualitative analyses

4-methylthioamphetamine obtained from the Netherlands was used to obtain gas chromatography-nitrogen phosphorus detection (GC-NPD), GC-mass spectrometry and HPLC-DAD analytical data, including retention index (RI) values for GC and HPLC, mass spectral data (molecular ion = 181) and UV spectral data (UV maxima = 205 and 255 nm). An in-house HPLC UV spectrum and retention index database and GC retention index database was used for the identification of other drugs and drug metabolites present.

In 1998, three patients presented to local hospitals exhibiting atypical symptoms of Ecstasy overdose. Physicians requested emergency drug screening in order to assist in diagnosis and possible treatment. Comprehensive drug screening of the plasma and urine specimens by GC-NPD, EMIT II immunoassay and HPLC-DAD was performed. In all cases, 4-MTA and two associated compounds were detected by GC-NPD and HPLC-DAD, in addition to other stimulants, MDMA, amphetamine and pseudoephedrine. An atracurium breakdown product was also detected owing to the use of atracurium while intubating the patient. At present there is no information regarding 4-MTA pharmacokinetics and the author believes these to be the first reported data concerning probable metabolites.

Using HPLC-DAD, 4-MTA was identified by retention index value (RI) and by UV spectral matching. The UV spectrum of 4-MTA is different from that of MDMA and other amphetamine-related compounds and has a UV maximum at 255 nm (see Fig. 2). Figure 3 shows the results of qualitative HPLC-DAD analysis of the urine specimens obtained at 210 nm. Figure 4 shows the results of spectral matching.

One of the observed associates of 4-MTA (4-MTA associate 1) has a spectrum virtually identical to that of 4-MTA, and may correspond to a hydroxy derivative of the parent compound. This would be consistent with the metabolism of amphetamine and other amphetamine derivatives, where hydroxylated metabolites are also produced.
The UV spectrum of 4-MTA associates 2 suggests that the chromophore has been disrupted, possibly by sulfoxidation (i.e. 4-MTA associate 2 could be 4-MTA sulfoxide). This theory was supported in part by oxidation of 4-MTA with hydrogen peroxide. Sulfoxidation is a common and relatively rapid reaction and observations of 4-MTA standards in various storage environments have indicated that 4-MTA is readily oxidized and hence unstable. It is therefore recommended that specimens containing 4-MTA be collected in fluoridated containers and kept at $-20^\circ\text{C}$ prior to analysis.

The presence of other ‘recreational’ drugs is not unexpected owing to the mode of abuse of 4-MTA. Therefore, as 4-MTA tablets invariably only contain 4-MTA, it can be inferred that the other substances detected were due to the ingestion of additional tablets or powder. Furthermore, although amphetamine was detected in two of the three cases analysed, amphetamine does not appear to be a metabolite of 4-MTA, as it was not detected in a related fatality where only 4-MTA was found at high concentrations in all specimens analysed, including postmortem urine. In this case, the peri- and postmortem blood concentrations were reported to be 4.2 mg/L and 4.6 mg/L, respectively.

Quantitative analyses
Using 20% acetonitrile isocratic conditions, 4-MTA eluted at 2.83 min and the 10 mg/L fenfluramine internal standard eluted at 6.09 min (see Fig. 5). A linear calibration curve was produced from the 4-MTA plasma standards at 220 nm. MDMA and amphetamine were analysed using alternative isocratic conditions because of their elution characteristics. The identification of all compounds was confirmed using both absolute retention time and UV spectral data. Studies concerning the extraction precision or recovery were not performed.

The results show that the plasma 4-MTA concentration ranged between 0.131 and 0.760 mg/L, and in all cases at the time of specimen collection the patients were in a serious clinical condition requiring ventilation and sedation after suffering convulsions (see Table 1). All patients were eventually discharged.

In Case 3, various timed plasma specimens were taken. Shortly after admission the patient was in severe respiratory distress and had a plasma 4-MTA concentration of 0.760 mg/L. The specimen subsequently taken at 07:15 showed a 4-MTA concentration of 0.280 mg/L, a further specimen taken at 14:10 (7 h later) showed that the plasma 4-MTA concentration had virtually halved (0.144 mg/L). The results

<table>
<thead>
<tr>
<th>Drugs detected (in urine)</th>
<th>Date collected</th>
<th>Time collected</th>
<th>Plasma MDMA concentration</th>
<th>Plasma amphetamine concentration</th>
<th>Plasma 4-MTA concentration</th>
<th>Clinical details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1 4-MTA MDMA</td>
<td>04.07.98</td>
<td>NK</td>
<td>60 $\mu$g/L</td>
<td>ND (&lt;20 $\mu$g/L)</td>
<td>189 $\mu$g/L</td>
<td>Delayed reaction, convulsions, ventilated</td>
</tr>
<tr>
<td>Case 2 4-MTA Amphetamine Pseudoephedrine</td>
<td>16.08.09</td>
<td>16:30</td>
<td>ND (&lt;20 $\mu$g/L)</td>
<td>50 $\mu$g/L</td>
<td>131 $\mu$g/L</td>
<td>Ventilated</td>
</tr>
<tr>
<td>Case 3 4-MTA Amphetamine MDMA</td>
<td>28.09.987</td>
<td>NK</td>
<td>NA</td>
<td>NA</td>
<td>760 $\mu$g/L</td>
<td>Convulsions, ventilated</td>
</tr>
<tr>
<td></td>
<td>28.09.98</td>
<td>07:15</td>
<td>40 $\mu$g/L</td>
<td>240 $\mu$g/L</td>
<td>280 $\mu$g/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28.09.98</td>
<td>14:10</td>
<td>NA</td>
<td>NA</td>
<td>144 $\mu$g/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28.09.98</td>
<td>17:15</td>
<td>20 $\mu$g/L</td>
<td>110 $\mu$g/L</td>
<td>154 $\mu$g/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30.09.98</td>
<td>NK</td>
<td>ND (&lt;20 $\mu$g/L)</td>
<td>ND</td>
<td>ND (&lt;50 $\mu$g/L)</td>
<td></td>
</tr>
</tbody>
</table>

$^1$Pseudoephedrine concentration not measured due to insufficient specimen. NK = not known; NA = specimen not analysed (e.g. insufficient sample volume); ND = not detected (limit of detection quoted); MDMA = 3,4-methylenedioxymethamphetamine.

Ann Clin Biochem 2001: 38
obtained from this particular patient suggest that 4-MTA has a plasma half-life of approximately 7 h. Interestingly, the concentration appeared to be slightly higher 3 h later (0.154 mg/L); this could be due to redistribution but did not appear to be an analytical anomaly. Furthermore, it can be seen that in all three cases there is a relatively low concentration of MDMA and/or amphetamine in the plasma, compared to 4-MTA. The toxicological relevance of this would depend on the pharmacokinetics of 4-MTA and its potential interaction with MDMA or amphetamine at various doses.

The author believes that the data presented here and those obtained from fatalities involving 4-MTA suggest that moderate toxicity may be associated with plasma 4-MTA concentrations of between 0.20 and 0.60 mg/L, severe toxicity with concentrations above 0.60 mg/L, and death with concentrations above 1.50 mg/L. However, further studies are required to confirm whether or not this is the case.

Acknowledgements
The author wishes to thank Drs Les King, Henk Huizer, Anneke Poortman, Allister Vale and Sally Bradberry for their assistance and discussions during this investigation.

REFERENCES
5 Elliott SP. Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). *J Anal Toxicol* 2000; 24: 85–9
7 Elliott SP. An initial review of 4-methylamphetamine analytical findings. *Bull TIAFT* 1999; 29: 7–9
10 Baselt RC. “Amphetamine” and “methyleneoxy-methamphetamine”. In: *Disposition of Toxic Drugs and Chemicals in Man*, 5th edn. California: Chemical Toxicology Institute, 2000

Accepted for publication 5 March 2001